Similar articles

• Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse.

  Natsume A, Mizuno M, Ryuke Y, Yoshida J. Natsume A, et al. Gene Ther. 1999 Sep;6(9):1626-33. doi: 10.1038/sj.gt.3300990. Gene Ther. 1999. PMID: 10490773
• [Antitumor efficacy of recombinant interferon-beta on human glioma].

  Miyao Y, Shimizu K, Okamoto Y, Matsui Y, Tsuda N, Yamada M, Tamura K, Mogami H. Miyao Y, et al. Gan To Kagaku Ryoho. 1987 Feb;14(2):490-4. Gan To Kagaku Ryoho. 1987. PMID: 3813577 Japanese.
• [Clinical trials of interferon-beta (MR-21) on malignant brain tumors].

  Takakura K. Takakura K. Nihon Gan Chiryo Gakkai Shi. 1987 May 20;22(4):801-8. Nihon Gan Chiryo Gakkai Shi. 1987. PMID: 3312440 Clinical Trial. Japanese. No abstract available.
• [Efficacy of interferon-beta and interleukin-2 as cytokines for malignant brain tumor treatment].

  Shitara N, Nakamura H, Genka S, Takakura K. Shitara N, et al. Gan To Kagaku Ryoho. 1987 Dec;14(12):3235-44. Gan To Kagaku Ryoho. 1987. PMID: 3318704 Review. Japanese.
• [Virally mediated immunotherapy as a component of combined treatment in malignant cerebral glioma].

  Kartashev AV, Vinogradov VM, Pozdniakov AV, Kiseleva LN, Iagunov AS. Kartashev AV, et al. Vopr Onkol. 2010;56(3):278-82. Vopr Onkol. 2010. PMID: 20804048 Review. Russian. No abstract available.